Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma

Figures & data

Table 1 Baseline characteristics of enrolled patients (n = 33)

Characteristic	Number (%)
Age (years)
Median	56
Range	43–70
Sex
Male	30 (90.9)
Female	3 (9.1)
ECOG performance status
0	22 (66.7)
1	11 (33.3)
Patient status
Recurrence/metastases after surgery	10 (30.3)
Unresectable tumor with metastases	23 (69.7)
Differentiation
Good	4 (12.1)
Moderate	13 (39.4)
Poor	14 (42.4)
Unknown	2 (6.1)
Number of metastatic sites
1	12 (36.4)
2	15 (45.5)
≥3	6 (18.2)
Site of metastatic disease
Lung	10 (30.3)
Liver	5 (15.2)
Bone	5 (15.2)
Distant lymph nodes	31 (93.9)
Other organ metastases	2 (6.1)

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

Figure 1 Progression-free survival curves for metastatic esophageal cancer patients treated with nanoparticle albumin-bound paclitaxel plus cisplatin (n = 33).

Figure 2 Overall survival curves for metastatic esophageal cancer patients treated with nanoparticle albumin-bound paclitaxel plus cisplatin (n = 33).

Table 2 Response for patients treated with Nab-PTX and DDP

Response	Number (%)	95% confidence interval
Complete response	–	–
Partial response	20 (60.6)	48.5–81.8
Stable disease	9 (27.3)	12.1–45.4
Progressive disease	4 (12.1)	3.0–30.3
Objective response rate	20 (60.6)	48.5–81.8
Disease control rate	29 (87.9)	69.7–97.0

Abbreviations: DDP, cisplatin; Nab-PTX, nanoparticle albumin-bound paclitaxel.

Table 3 Toxicity (n = 33)

Adverse event, N (%)	Grade 1	Grade 2	Grade 3	Grade 4
Leucopenia	7 (21.2)	8 (24.2)	1 (3.0)	–
Neutropenia	13 (39.4)	7 (21.2)	1 (3.0)	–
Thrombocytopenia	1 (3.0)	–	–	–
Anemia	8 (24.2)	–	–	–
Sensory neuropathy	5 (15.2)	2 (6.1)	1 (3.0)	–
Bilirubin	2 (6.1)	1 (3.0)	–	–
Nausea/vomiting	15 (45.5)	11 (33.3)	1 (3.0)	–
Fever	–	–	–	–
Hepatic functions	1 (3.0)	–	–	–

Table 4 Comparison of current study with other reports on first-line chemotherapy regimens for metastatic ESCC

Regimen	N	ORR (%)	PFS/TTP (months)	OS (months)	Author
Nab-PTX+DDP	33	60.6	6.2	15.5	Current study
PTX+CAP
1st line	12	75.0	5.23	14.3	Yun et al^Citation26
2nd line	20	45.0	4.54	8.4
CAP+DDP	72	51.4	4.2	12.0	Lee et al^Citation32
TXT+DDP+5-Fu	39	66.6	7.0	13.0	Takahashi et al^Citation27
ADM+5-Fu+DDP	41	43.9	NR	10.2	Honda et al^Citation33
PTX+NDP (ESCC = 46)	48	41.7	6.1	11.5	Cao et al^Citation28
PTX+NDP (ESCC = 33)	36	43.6	6.1	10.3	Gong et al^Citation29
5-Fu+DDP	32	13.0	3.6	5.5	Lorenzen et al^Citation34
5-Fu+DDP+cetuximab	32	19.0	5.9	9.5
OXA+CAP	64	43.8	4.0	10.0	Qin et al^Citation35
CAP+DDP	45	57.8	4.7	11.2	Lee et al^Citation36
PTX+DDP	35	48.6	7.0	13.0	Zhang et al^Citation30
TXT+DDP
ESCC	10	40.0	4.3	6.9	Laack et al^Citation31
EADC	6	20.0

Abbreviations: 5-Fu, 5-fluorouracil; ADM, doxorubicin; CAP, capecitabine; DCR, disease control rate; DDP, cisplatin; EADC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; N, number; Nab-PTX, nanoparticle albumin-bound paclitaxel; NDP, nedaplatin; NR, not reported; ORR, objective response rate; OS, overall survival; OXA, oxaliplatin; PFS, progression-free survival; TTP, time to progression; TXT, docetaxel; PTX, paclitaxel.

YunTHanJYLeeJSPhase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinomaBMC Cancer20111138521888637

 PubMed Web of Science ®Google Scholar

LeeSParkYHKimKHThymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinomaBr J Cancer2010103684585120700125

 PubMed Web of Science ®Google Scholar

TakahashiHArimuraYYamashitaKPhase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinomaJ Thorac Oncol20105112212819898259

 PubMed Web of Science ®Google Scholar

HondaMMiuraAIzumiYDoxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinomaDis Esophagus201023864164520545978

 PubMed Web of Science ®Google Scholar

CaoWXuCLouGA phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancerJpn J Clin Oncol200939958258719509000

 PubMed Web of Science ®Google Scholar

GongYRenLZhouLPhase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinomaCancer Chemother Pharmacol200964232733319048253

 PubMed Web of Science ®Google Scholar

LorenzenSSchusterTPorschenRCetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische OnkologieAnn Oncol200920101667167319549707

 PubMed Web of Science ®Google Scholar

QinTJAnGLZhaoXHCombined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancerWorld J Gastroenterol200915787187619230050

 PubMed Web of Science ®Google Scholar

LeeJImYHChoEYA phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinomaCancer Chemother Pharmacol2008621778417762932

 PubMed Web of Science ®Google Scholar

ZhangXShenLLiJLiYLiJJinMA phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagusAm J Clin Oncol2008311293318376224

 PubMed Web of Science ®Google Scholar

LaackEAndritzkyBDürkHDocetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot studyOnkologie2005281264765016330888

 PubMedGoogle Scholar